Group One Trading’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.2M | Sell |
130,400
-24,700
| -16% | -$1.3M | 0.01% | 1139 |
|
|
2025
Q4 | $8.13M | Buy |
155,100
+11,700
| +8% | +$701K | 0.01% | 1088 |
|
|
2025
Q3 | $9.29M | Buy |
143,400
+27,500
| +24% | +$1.58M | 0.02% | 957 |
|
|
2025
Q2 | $5.64M | Buy |
115,900
+49,700
| +75% | +$1.92M | 0.01% | 1241 |
|
|
2025
Q1 | $2.25M | Sell |
66,200
-50,300
| -43% | -$2.13M | 0.01% | 1718 |
|
|
2024
Q4 | $4.59M | Buy |
116,500
+20,600
| +21% | +$973K | 0.01% | 1232 |
|
|
2024
Q3 | $4.51M | Sell |
95,900
-11,400
| -11% | -$578K | 0.01% | 1077 |
|
|
2024
Q2 | $5.8M | Sell |
107,300
-4,800
| -4% | -$278K | 0.02% | 716 |
|
|
2024
Q1 | $7.64M | Sell |
112,100
-119,600
| -52% | -$8.56M | 0.03% | 566 |
|
|
2023
Q4 | $14.5M | Buy |
231,700
+120,700
| +109% | +$6.67M | 0.04% | 484 |
|
|
2023
Q3 | $5.04M | Sell |
111,000
-18,900
| -15% | -$976K | 0.02% | 937 |
|
|
2023
Q2 | $7.29M | Buy |
129,900
+38,600
| +42% | +$2.19M | 0.02% | 706 |
|
|
2023
Q1 | $4.13M | Sell |
91,300
-7,100
| -7% | -$345K | 0.01% | 961 |
|
|
2022
Q4 | $4M | Sell |
98,400
-45,000
| -31% | -$2.39M | 0.01% | 1301 |
|
|
2022
Q3 | $9.37M | Sell |
143,400
-123,100
| -46% | -$8.92M | 0.02% | 763 |
|
|
2022
Q2 | $16.2M | Sell |
266,500
-133,300
| -33% | -$7.84M | 0.03% | 577 |
|
|
2022
Q1 | $25.1M | Sell |
399,800
-205,100
| -34% | -$12.9M | 0.02% | 501 |
|
|
2021
Q4 | $45.8M | Sell |
604,900
-256,600
| -30% | -$22.4M | 0.04% | 338 |
|
|
2021
Q3 | $96.4M | Buy |
861,500
+17,700
| +2% | +$2.22M | 0.1% | 126 |
|
|
2021
Q2 | $137M | Buy |
843,800
+3,100
| +0.4% | +$377K | 0.16% | 73 |
|
|
2021
Q1 | $102M | Buy |
840,700
+485,300
| +137% | +$73.3M | 0.15% | 85 |
|
|
2020
Q4 | $54.4M | Buy |
355,400
+333,600
| +1,530% | +$39.4M | 0.09% | 168 |
|
|
2020
Q3 | $1.82M | Sell |
21,800
-1,800
| -8% | -$160K | 0.01% | 1686 |
|
|
2020
Q2 | $1.73M | Buy |
23,600
+3,900
| +20% | +$228K | 0.01% | 1574 |
|
|
2020
Q1 | $835K | Sell |
19,700
-23,400
| -54% | -$1.21M | 0.01% | 1656 |
|
|
2019
Q4 | $2.63M | Buy |
43,100
+34,800
| +419% | +$1.9M | 0.02% | 1084 |
|
|
2019
Q3 | $340K | Sell |
8,300
-1,200
| -13% | -$57.3K | ﹤0.01% | 2664 |
|
|
2019
Q2 | $447K | Sell |
9,500
-16,300
| -63% | -$651K | ﹤0.01% | 2222 |
|
|
2019
Q1 | $922K | Buy |
25,800
+4,000
| +18% | +$138K | 0.01% | 1465 |
|
|
2018
Q4 | $623K | Sell |
21,800
-61,400
| -74% | -$2.13M | 0.01% | 1850 |
|
|
2018
Q3 | $3.69M | Sell |
83,200
-8,400
| -9% | -$440K | 0.03% | 753 |
|
|
2018
Q2 | $5.38M | Buy |
91,600
+36,800
| +67% | +$2.1M | 0.05% | 502 |
|
|
2018
Q1 | $2.5M | Buy |
54,800
+47,800
| +683% | +$1.97M | 0.03% | 850 |
|
|
2017
Q4 | $164K | Buy |
+7,000
| New | +$133K | ﹤0.01% | 3051 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Group One Trading's CRSP Position: Q1 2026 in Review
Group One Trading increased its CRISPR Therapeutics (CRSP) stake by 2.2% in Q1 2026, buying an estimated $108K and bringing the position to 96,001 shares worth $4.57M. The position accounts for 0.01% of the portfolio, ranked #1370.
Group One Trading first reported a position in CRSP in Q4 2017 and has held it in 26 quarters since. The position peaked at $64.7M in Q2 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.
- Group One Trading held 96,001 shares of CRISPR Therapeutics worth $4.57M as of Q1 2026.
- Group One Trading bought 2,047 CRISPR Therapeutics shares in Q1 2026, an estimated $108K.
- CRISPR Therapeutics made up 0.01% of Group One Trading's portfolio in Q1 2026, its #1370 holding.
- Group One Trading first reported a position in CRISPR Therapeutics in Q4 2017 and has held it in 26 quarters since.
- Group One Trading's CRISPR Therapeutics position peaked at $64.7M in Q2 2021.
- 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.
Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.